The association of the Klotho polymorphism rs9536314 with parameters of calcium-phosphate metabolism in patients on long-term hemodialysis

References

• Rassa AC, Horne BD, McCubrey RO, et al. Novel stratification of mortality risk by kidney disease stage. Am J Nephrol. 2015;42:443–450.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Salmeron D, Martin-Molo A, et al. A new data analysis system to quantify associations between biochemical parameters of chronic kidney disease – Mineral bone disease. PLos One. 2016;11:e0146801.
   Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218.
   PubMed Web of Science ®Google Scholar
• Hardcastle MR, Dittmer KE. Factor 23: A new dimension to diseases of calcium-phosphorus metabolism. Vet Pathol. 2015;52:770–784.
   PubMed Web of Science ®Google Scholar
• Smith ER. The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol. 2014;9:1283–1303.
   PubMed Web of Science ®Google Scholar
• Hu MC, Shizaki k, Kuro-o Moe OW. Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013;75:503–533.
   PubMed Web of Science ®Google Scholar
• Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone. 2007;40:1190–1195.
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Nagano N, Urakawa J, et al. Direct evidence for a causative role of FGF23 in the normal renal phosphate handling and Vitamin D metabolism in rats witch end-stage chronic kidney disease. Kidney Int. 2010;70:975–980.
   Web of Science ®Google Scholar
• Kuro-o M, Matsumara Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;6655:45–51.
   Web of Science ®Google Scholar
• Nebeshima Y. Chellenge of overcoming aging-related disorders. J Dermatol Sci. 2000;24:15–21.
   Web of Science ®Google Scholar
• Gutierrez OM, Mannstadt M, Isakova T. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592.
   PubMed Web of Science ®Google Scholar
• Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res. 2005;96:412–418.
   PubMed Web of Science ®Google Scholar
• Ko GJ, Lee YM, Lee EA, et al. WDPA. The association of Klotho gene polymorphism with the mortality of patients on maintenance dialysis. Clin Nephrol. 2013;80:263–269.
   PubMed Web of Science ®Google Scholar
• Nowak A, Friedrich B, Artunc F, et al. Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients. PLoS One. 2014;9:0100688.
   PubMed Web of Science ®Google Scholar
• Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-hemodialysis patients associated factors and survival consequences. Nephrol Dial Transplant. 2009;24:948–955.
   PubMed Web of Science ®Google Scholar
• Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroksyvitamin in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;7:2116–2124.
   Web of Science ®Google Scholar
• Mensenkamp AR, Hoenderop JG, Bindels RJ. TRPV5, the gateway to Ca 2+ homeostasis. Handb Exp Pharmacol. 2007;179:207–220.
   PubMedGoogle Scholar
• Arking Krebsova Macek, et all. Association of human aging with a functional variant of Klotho. Proc Natl Acad Sci USA. 2002;99:856–861.
   PubMed Web of Science ®Google Scholar
• Bartke A. Long-lived Klotho mice: New insights into the roles of IGF-1 and insulin in ageing. Trends Endocrinol Metab. 2006;2:33–35.
   Web of Science ®Google Scholar
• Xie B, Chen J, Liu B. Klotho acts as a tumor suppressor in cancers. Pathol Oncol Res. 2013;4:611–617.
   Web of Science ®Google Scholar
• Friedman DJ, Afkarian M, Tamez H, et al. Klotho variants and chronic hemodialysis mortality. J Bone Miner Res. 2009;24:1847–1855.
   PubMed Web of Science ®Google Scholar
• Shimoyama Y, Taki K, Mitsuda Y, Tsuruta Y, Hamajima N, Niwa T. Klotho gene polymorphism G-395A and C1818T are associated with low-density lipoprotein cholesterol and uric acid in Japanese hemodialysis patients. Am J Nephrol. 2009;4:383–388.
   Web of Science ®Google Scholar
• Cancela A, Oliveira R, Graciolli F. Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysis. Nephron Clin Pract. 2011;1:74–82.
   Google Scholar
• Ashikaga E, Honda H, Suzuki H, et al. Impact of fibroblast growth factor 23 on lipids and arteriosclerosis in hemodialysis patients. Ther Apher Dial. 2010;3:315–322.
   Web of Science ®Google Scholar
• Nagano N, Miyata S, Abe M, et al. Effect of manipulating serum phosphorous with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006;3:531–337.
   Web of Science ®Google Scholar
• Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013.
   PubMed Web of Science ®Google Scholar
• Fliser D, Kollerits B, Neyer U, et al.; MMKD Study Group. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease. J Am Soc Nephrol. 2007;9:2600–2608.
   Web of Science ®Google Scholar
• Braithwaite V, Jarjou L, Goldberg G. Iron status and fibroblast growth factor 23 in Gambian children. Bone. 2012;6:1351–1356.
   Web of Science ®Google Scholar
• Takeda Y, Komaba H, Goto S, et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol. 2011;5:421–426.
   Web of Science ®Google Scholar
• Yamamoto S, Okada Y, Mori H, Fukumoto S, Tanaka Y. Fibroblast growth factor 23 – related osteomalacia caused by the prolonged administration of sacchared ferric oxide. Intern Med. 2012;17:2375–2378.
   Web of Science ®Google Scholar
• Shimizu Y, Tada Y, Yamauchi M. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: Another form of FGF23-related hypophosphatemia. Bone. 2009;4:814–816.
   Web of Science ®Google Scholar
• Agrawal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int. 2006;7:1259–1263.
   Web of Science ®Google Scholar
• Koh N, Fujimori T, Nishiguchi S. Severely reduced production of Klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001;4:1015–1020.
   Web of Science ®Google Scholar